Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Breast Neoplasms 6Neuroendocrine Tumors 5Neoplasm Metastasis 3Carcinoma, Renal Cell 3Tuberous Sclerosis 2Triple Negative Breast Neoplasms 2Recurrence 2Glioma 2Endometrial Neoplasms 2Adenoma, Islet Cell 2von Hippel-Lindau Disease 1Vascular Malformations 1Unilateral Breast Neoplasms 1Thymus Neoplasms 1Seizures 1Sarcoma, Kaposi 1Sarcoma 1Nevus 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Metastatic Digestive System Neuroendocrine Tumor G1 1Meningioma 1Lymphangioma 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Kidney Neoplasms 1Hemangioma 1Hemangioendothelioma 1Hamartoma Syndrome, Multiple 1

Interventions

Everolimus 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Hamartoma Syndrome, Multiple × Everolimus × 90 days × Clear all
NCT07218575 2026-06-04

Double-Blind Trial of Everolimus for Improving Social Abilities in PTEN Germline Mutations

Boston Children's Hospital

Phase 2/3 Not yet recruiting
60 enrolled

Autistic Disorder, Hamartoma Syndrome, Multiple

Data powered by HemOnc (CC BY 4.0) Colophon âš¡